Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Buy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of Rezpeg
Nektar Therapeutics (NKTR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian ...
Gilead, LEO Pharma Enter Strategic Partnership To Accelerate Development Of Oral STAT6 Program
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
Pharmabiz21h
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
The Healthy on MSN13h
The 10 Itches You Should Never, Ever Scratch
An itch can drive you absolutely crazy, but there are times when scratching only makes it worse—throwing your body's ...